Talimogene laherparepvec for treating unresectable metastatic melanoma

  • Technology appraisal guidance
  • TA410
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Talimogene laherparepvec is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (stage 3B, 3C or 4M1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if:

  • treatment with systemically administered immunotherapies is not considered the best option by a multidisciplinary team and

  • the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.

1.2 This guidance is not intended to affect the position of patients whose treatment with talimogene laherparepvec was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.